Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats irritable bowel syndrome with constipation (IBS-C). Sold as Ibsrela, Xphozah. Every FDA application for this active ingredient. Boxed warning
As of Nov 22, 2026, FDA lists 2 applications for Tenapanor hydrochloride (sold as Ibsrela, Xphozah), first approved Sep 12, 2019, with 0 new uses approved and 1 published complete response letter.
Each condition ChEMBL records for this drug, with the furthest stage reached and the trials it cites; approved means approved for that use somewhere, not necessarily in the US
What state Medicaid programs paid pharmacies in 2025, before rebates, by product name; see every drug
Ibsrela
$66.5M for 33,575 prescriptions, +105% on 2024
Xphozah
$37.5M for 11,632 prescriptions, +82% on 2024
What pharmacies pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
Ibsrela 50 mg tablet: $32.54 per unitBrand · +9% in a year
How its trials ended
14 ClinicalTrials.gov studies testing it, classified by TrialPanorama, partly automatically, so some labels are wrong
Of the 7 whose ending is known, 100% met their primary endpoint, 0% missed it and 0% stopped early.
Met its primary endpoint750%Met its primary endpointCount7Share50%
Ongoing536%OngoingCount5Share36%
Completed, result not reported214%Completed, result not reportedCount2Share14%
Adverse event reports (FAERS)
Cases reported to FDA naming this drug as the primary suspect, 2025 Q4 to 2026 Q3, from FDA's quarterly files. A report does not show the drug caused the event.
First approved in Japan 48 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Phozevel, new ingredientDrugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease on dialysis. · Kyowa Kirin Co., Ltd. · Sep 25, 2023 · Review report
Approvals in Canada (Health Canada)
First approved in Canada 7 months after the US. New drug submissions since 1994, matched by ingredient; see all Canadian approvals
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered.Drugs@FDA